const e=()=>[{title:"ğŸ“– Management Summary",points:["**TAB_START:Summary**","## <u>**Chorioamnionitis - Management Protocol**</u>","","### <u>**1. Diagnosis - Triple Criteria**</u>","â€¢ **Maternal Fever**: >38Â°C (100.4Â°F) plus two or more:","â€¢ **Maternal Tachycardia**: >100 bpm, fetal tachycardia >160 bpm","â€¢ **Uterine Tenderness**: On palpation, purulent/foul amniotic fluid","â€¢ **Laboratory**: Elevated WBC >15,000, elevated CRP/PCT","","### <u>**2. Emergency Treatment**</u>","â€¢ **IV Antibiotics**: Ampicillin 2g q6h + Gentamicin 5mg/kg q24h","â€¢ **Alternative**: Clindamycin 900mg q8h + Gentamicin (penicillin allergy)","â€¢ **Expedite Delivery**: Regardless of gestational age","â€¢ **Continue Postpartum**: Until fever-free 48 hours","","### <u>**3. Maternal-Fetal Monitoring**</u>","â€¢ **Maternal**: Vital signs q1h, urine output, sepsis watch","â€¢ **Fetal**: Continuous CTG, prepare for neonatal resuscitation","â€¢ **Delivery**: Vaginal preferred if progressing, cesarean if indicated","â€¢ **Neonatal**: Immediate evaluation for sepsis, blood cultures","","---","","**âš ï¸ Key Management Points:**","â€¢ Time-sensitive emergency requiring immediate antibiotics","â€¢ Delivery expedited to prevent maternal sepsis and fetal complications","â€¢ High risk of neonatal sepsis - immediate pediatric involvement","**TAB_END**"]},{title:"ğŸ”¥ Chorioamnionitis - Comprehensive Clinical Overview",points:["ğŸ”¥ **Definition**: Chorioamnionitis is acute inflammation of the chorion, amnion, and amniotic fluid (intra-amniotic infection) characterized by microbial invasion of amniotic cavity leading to maternal fever, fetal tachycardia, and systemic inflammatory response. It represents a time-critical obstetric emergency with high maternal-fetal morbidity and mortality if untreated","ğŸ“Š **Incidence**: 1-5% all deliveries, 5-10% preterm births, 15-25% very preterm","ğŸ’€ **Maternal Mortality**: 1-3% if treated, 15-20% if untreated","ğŸ¤° **Risk Factors**: Prolonged ROM, multiple vaginal exams, prolonged labor","ğŸ¦  **Microbiology**: Polymicrobial - E.coli (30%), GBS (25%), anaerobes (20%)","âš¡ **Time-Critical**: Rapid progression to sepsis, multi-organ failure","ğŸ‘¶ **Fetal Impact**: 15-25% neonatal sepsis, increased cerebral palsy risk","ğŸ“ˆ **Rising Incidence**: Associated with increased survival of extreme preterm infants"]},{title:"ğŸ“Š Chorioamnionitis Epidemiology - Global & Kenya Context",subsections:[{title:"ğŸŒ Global Epidemiology",points:["ğŸ“ˆ **Worldwide Incidence**: 1-5% of all pregnancies, 15-25% preterm births","ğŸ’€ **Maternal Mortality**: 1-3% treated cases, 10-20% severe sepsis","ğŸ¦  **Pathogen Patterns**: E.coli (30%), GBS (25%), Enterococcus (15%), anaerobes (20%)","â° **Gestational Age**: Inverse relationship - higher rates in preterm","ğŸ¥ **Healthcare Setting**: 2-3x higher in resource-limited settings","ğŸ“Š **Neonatal Impact**: 20-40% early-onset sepsis, 15% cerebral palsy","ğŸŒ¡ï¸ **Seasonal**: No significant seasonal variation","ğŸ“ˆ **Trends**: Increasing with improved preterm survival"]},{title:"ğŸ‡°ğŸ‡ª Kenya Epidemiological Profile",points:["ğŸ“Š **National Incidence**: 8-15% deliveries (higher than global average)","ğŸ’€ **Maternal Mortality**: 5-8% case fatality rate","ğŸ¦  **Local Pathogens**: E.coli, GBS, Klebsiella, anaerobes","ğŸ¥ **Healthcare Factors**: Delayed presentation, limited monitoring","ğŸ’Š **Antibiotic Resistance**: Increasing ESBL-producing organisms","ğŸŒ§ï¸ **Seasonal**: Slight increase during rainy seasons","ğŸ“ˆ **Risk Factors**: HIV (15-20%), malnutrition, poor hygiene","ğŸ˜ï¸ **Urban vs Rural**: Higher rates in urban slums"]},{title:"ğŸ”ï¸ Nakuru County Specific Profile",points:["ğŸ“ **County Burden**: 600-800 cases annually","ğŸ¥ **Healthcare Access**: Referral hospital, limited ICU facilities","ğŸ‘¥ **Population Risk**: Mixed urban-rural, varied socioeconomic","ğŸ“Š **Outcomes**: 85% survival with treatment, 65% without","ğŸ’Š **Treatment**: Standard protocols, antibiotic availability","ğŸ¯ **Prevention**: Improved antenatal care, hygiene education","ğŸ“ˆ **Trends**: Stable incidence, improving outcomes","ğŸ¤ **Community**: Traditional birth attendant education"]}]},{title:"ğŸ”¬ Pathogenesis of Chorioamnionitis",subsections:[{title:"ğŸ¦  Routes of Microbial Invasion",points:["â¬†ï¸ **Ascending (Most Common - 95%)**:","  â€¢ Vaginal/cervical bacteria ascend through cervix","  â€¢ Penetrate fetal membranes, enter amniotic cavity","  â€¢ Risk factors: cervical insufficiency, membrane rupture","","ğŸ©¸ **Hematogenous (3-4%)**:","  â€¢ Maternal bacteremia, transplacental spread","  â€¢ Listeria monocytogenes, Streptococcus agalactiae","  â€¢ More common in early pregnancy","","â¬‡ï¸ **Descending (<1%)**:","  â€¢ Retrograde spread from peritoneal cavity","  â€¢ Following procedures (amniocentesis, PUBS)","","ğŸ”„ **Direct Extension (Rare)**:","  â€¢ Adjacent organ infection (appendicitis, UTI)","  â€¢ Iatrogenic contamination during procedures"]},{title:"ğŸ§¬ Molecular Pathogenesis",points:["ğŸ¦  **Bacterial Adherence**: Fimbriae, adhesins bind to fetal membranes","ğŸ’¥ **Membrane Degradation**: Bacterial proteases, elastases weaken amnion","ğŸ”¥ **Inflammatory Cascade**: TNF-Î±, IL-1Î², IL-6, IL-8 upregulation","âš¡ **Complement Activation**: C3a, C5a amplify inflammatory response","ğŸŒŠ **Prostaglandin Release**: PGE2, PGF2Î± trigger uterine contractions","ğŸ’€ **Cellular Apoptosis**: Programmed cell death in amnion, chorion","ğŸ§¬ **Matrix Metalloproteinases**: Collagenases degrade membrane structure","ğŸ”„ **Positive Feedback**: Inflammation â†’ membrane weakness â†’ bacterial invasion"]},{title:"ğŸ¤° Maternal-Fetal Interface Disruption",points:["ğŸŒŠ **Amniotic Fluid Changes**: Increased WBC, decreased glucose, elevated LDH","ğŸ”¥ **Placental Inflammation**: Villitis, intervillositis, decidual inflammation","ğŸ’¥ **Barrier Breakdown**: Loss of antimicrobial peptides, immune dysfunction","ğŸ§¬ **Fetal Response**: Fetal inflammatory response syndrome (FIRS)","âš¡ **Cytokine Storm**: Maternal and fetal cytokine elevation","ğŸ©¸ **Vascular Changes**: Increased permeability, thrombosis risk","ğŸ’€ **Tissue Necrosis**: Hemorrhage, necrosis of membranes","ğŸ”„ **Labor Onset**: Inflammatory mediators trigger preterm labor"]}]},{title:"ğŸ›¡ï¸ Immunity Against Chorioamnionitis",subsections:[{title:"ğŸŒŠ Normal Amniotic Cavity Defense",points:["ğŸ›¡ï¸ **Physical Barriers**: Intact fetal membranes, cervical mucus plug","ğŸ§¬ **Antimicrobial Peptides**: Defensins, lactoferrin in amniotic fluid","ğŸ½ï¸ **Cellular Immunity**: Amniotic fluid macrophages, neutrophils","ğŸ’€ **Complement System**: Classical and alternative pathway activation","ğŸ”¥ **Cytokine Network**: IL-10, TGF-Î² maintain immune homeostasis","ğŸ¦  **Antimicrobial Proteins**: Lysozyme, phospholipase A2","âš¡ **Rapid Response**: Immediate neutrophil recruitment to infection","ğŸ§¬ **Antibody Transfer**: Maternal IgG crosses placenta"]},{title:"ğŸ¤° Pregnancy-Associated Immune Changes",points:["ğŸ“‰ **Systemic Immunosuppression**: Reduced maternal immune surveillance","ğŸ”„ **Local Immune Tolerance**: Prevent rejection of fetal tissues","ğŸ›¡ï¸ **Barrier Function**: Cervical mucus changes, membrane thinning","ğŸ½ï¸ **Macrophage Polarization**: M2 phenotype, reduced antimicrobial activity","âš¡ **Complement Changes**: Reduced complement activity late pregnancy","ğŸ”¥ **Inflammatory Balance**: Anti-inflammatory bias to protect fetus","ğŸ’€ **NK Cell Function**: Reduced natural killer cell activity","ğŸ§¬ **Antibody Production**: Altered humoral immune responses"]},{title:"âš”ï¸ Immune Dysfunction in Chorioamnionitis",points:["ğŸ’¥ **Overwhelming Inflammation**: Cytokine storm overwhelms defenses","ğŸ¦  **Bacterial Evasion**: Biofilm formation, immune evasion mechanisms","ğŸ”„ **Immune Exhaustion**: Prolonged inflammation depletes immune cells","ğŸ§¬ **Complement Consumption**: Rapid complement depletion","ğŸ’€ **Tissue Damage**: Inflammatory mediators damage host tissues","âš¡ **Systemic Effects**: SIRS, sepsis, multi-organ dysfunction","ğŸŒŠ **Barrier Loss**: Complete breakdown of protective mechanisms","ğŸ”¥ **Persistent Inflammation**: Self-perpetuating inflammatory cycle"]}]},{title:"ğŸ”¬ Pathology of Chorioamnionitis",subsections:[{title:"ğŸŒŠ Amniotic Membrane Changes",points:["ğŸ”¥ **Acute Inflammation**: Neutrophil infiltration of amnion, chorion","ğŸ’¥ **Membrane Necrosis**: Coagulative necrosis, hemorrhage","ğŸ§¬ **Cellular Infiltrate**: PMNs, lymphocytes, plasma cells","ğŸŒŠ **Edema Formation**: Interstitial fluid accumulation","ğŸ’€ **Tissue Destruction**: Loss of membrane integrity, thinning","ğŸ”„ **Fibroblast Response**: Attempted repair, collagen deposition","âš¡ **Vascular Changes**: Congestion, thrombosis, hemorrhage","ğŸ¯ **Staging**: Subchorioamnionitis â†’ chorioamnionitis â†’ necrotizing"]},{title:"ğŸŒŠ Amniotic Fluid Pathology",points:["ğŸ”¢ **Cellular Changes**: WBC >500/Î¼L, neutrophil predominance","ğŸ§ª **Biochemical**: Glucose <15mg/dL, elevated LDH, protein","ğŸ¦  **Microbiology**: Positive cultures in 70-80% clinical cases","ğŸ”¥ **Inflammatory Markers**: Elevated IL-6, IL-8, TNF-Î±","ğŸ’§ **Physical Properties**: Turbid, purulent, foul odor","ğŸ§¬ **Molecular**: Elevated matrix metalloproteinases","âš¡ **Endotoxin**: Bacterial lipopolysaccharide detection","ğŸ“Š **Gram Stain**: Bacteria visible in 50-60% cases"]},{title:"ğŸŒŠ Placental Pathological Changes",points:["ğŸ”¥ **Villitis**: Inflammatory infiltrate in placental villi","ğŸ©¸ **Intervillositis**: Maternal inflammatory cells in intervillous space","ğŸ’¥ **Decidual Inflammation**: Chronic deciduitis, plasma cell infiltrate","ğŸŒŠ **Funisitis**: Umbilical cord inflammation, Wharton's jelly edema","ğŸ’€ **Vascular Lesions**: Thrombosis, infarction, hemorrhage","ğŸ§¬ **Chronic Changes**: Fibrosis, calcification, chronic villitis","âš¡ **Fetal Response**: Fetal vasculitis, inflammatory cell migration","ğŸ¯ **Grading**: Amsterdam criteria - stages 1-3 severity"]},{title:"ğŸ§¬ Histopathological Features",points:["ğŸ”¥ **Acute Inflammation**: Neutrophil predominance early phase","ğŸŒŠ **Chronic Inflammation**: Lymphocytes, plasma cells later","ğŸ’€ **Necrosis Pattern**: Coagulative necrosis, tissue destruction","ğŸ§¬ **Bacterial Visualization**: Gram-positive, gram-negative organisms","âš¡ **Vascular Changes**: Endothelial swelling, thrombosis","ğŸ”„ **Repair Response**: Fibroblast proliferation, scarring","ğŸ’¥ **Hemorrhage**: Acute bleeding, hemosiderin deposition","ğŸ¯ **Immunohistochemistry**: CD68+ macrophages, CD15+ neutrophils"]}]},{title:"ğŸ©º Clinical Presentation - Recognition & Assessment",subsections:[{title:"ğŸ”¥ Classic Clinical Triad",points:["ğŸŒ¡ï¸ **Maternal Fever**: >38Â°C (100.4Â°F) - most common sign (95%)","ğŸ’“ **Fetal Tachycardia**: >160 bpm baseline (80-85% cases)","ğŸ’“ **Maternal Tachycardia**: >100 bpm (70-80% cases)","âš ï¸ **Complete Triad**: Present in only 50-60% of cases","ğŸš¨ **Early Signs**: May be subtle, high index of suspicion needed","ğŸ“ˆ **Progressive**: Symptoms worsen without treatment","â° **Timing**: Can occur antepartum, intrapartum, or postpartum","ğŸ¯ **Sensitivity**: Clinical diagnosis 70-80% sensitive"]},{title:"ğŸ” Additional Clinical Features",points:["ğŸ¤² **Uterine Tenderness**: Fundal tenderness on palpation (60-70%)","ğŸ’§ **Amniotic Fluid Changes**: Purulent, foul-smelling fluid (40-50%)","ğŸ©¸ **Vaginal Discharge**: Purulent, malodorous (30-40%)","ğŸ¤¢ **Constitutional Symptoms**: Nausea, vomiting, malaise","ğŸ’ª **Myalgia**: Generalized body aches, fatigue","ğŸ§  **Mental Status**: Confusion, irritability in severe cases","ğŸ« **Respiratory**: Tachypnea if developing sepsis","ğŸ”¥ **Chills/Rigors**: Severe shaking, teeth chattering"]},{title:"âš ï¸ Severity Assessment Criteria",points:["ğŸŸ¢ **Mild Chorioamnionitis**:","  â€¢ Low-grade fever 38-38.5Â°C","  â€¢ Minimal uterine tenderness","  â€¢ Stable maternal vitals","","ğŸŸ¡ **Moderate Chorioamnionitis**:","  â€¢ Fever 38.5-39Â°C","  â€¢ Moderate uterine tenderness","  â€¢ Fetal tachycardia present","","ğŸ”´ **Severe Chorioamnionitis**:","  â€¢ High fever >39Â°C","  â€¢ Severe uterine tenderness","  â€¢ Signs of sepsis: hypotension, altered mental status","  â€¢ Multi-organ dysfunction"]},{title:"ğŸ¤° Intrapartum vs Antepartum Presentation",points:["âš¡ **Intrapartum (80-85%)**:","  â€¢ Develops during active labor","  â€¢ Associated with prolonged ROM, multiple exams","  â€¢ Rapid progression, immediate delivery needed","","ğŸ¤° **Antepartum (15-20%)**:","  â€¢ Presents before labor onset","  â€¢ Often associated with preterm ROM","  â€¢ May trigger spontaneous preterm labor","","ğŸ¤± **Postpartum**:","  â€¢ Persistence of fever >24 hours postdelivery","  â€¢ Endometritis component common","  â€¢ Requires extended antibiotic therapy"]}]},{title:"ğŸ” Examination Findings",subsections:[{title:"ğŸŒ¡ï¸ Vital Signs Assessment",points:["ğŸŒ¡ï¸ **Temperature**: Fever >38Â°C, may spike to >40Â°C","ğŸ’“ **Pulse**: Maternal tachycardia >100 bpm, weak in sepsis","ğŸ« **Respiratory**: Tachypnea >24/min if sepsis developing","ğŸ©¸ **Blood Pressure**: Normal early, hypotension in sepsis","ğŸ“Š **Oxygen Saturation**: Usually normal unless ARDS","ğŸ§  **Mental Status**: Alert to confused, GCS if severe","ğŸ’§ **Perfusion**: Capillary refill, skin color assessment","âš–ï¸ **Weight**: Rapid weight gain if fluid retention"]},{title:"ğŸ¤² Abdominal & Uterine Examination",points:["ğŸ¤² **Fundal Tenderness**: Exquisite tenderness over uterine fundus","ğŸ“ **Uterine Size**: Appropriate for gestational age","ğŸ’“ **Uterine Activity**: May have increased irritability, contractions","ğŸŒŠ **Fluid Assessment**: Oligohydramnios possible with membrane rupture","ğŸ”„ **Fetal Movement**: May be reduced with fetal compromise","ğŸ’¥ **Guarding**: Abdominal rigidity in severe cases","ğŸ¯ **Rebound**: Peritoneal signs if extensive inflammation","ğŸ“Š **Bowel Sounds**: May be reduced if developing ileus"]},{title:"ğŸ” Pelvic Examination Findings",points:["ğŸŒ¡ï¸ **Vaginal Temperature**: Increased warmth","ğŸ’§ **Discharge**: Purulent, foul-smelling amniotic fluid","ğŸ” **Cervical Assessment**: Dilatation, effacement status","ğŸ©¸ **Bleeding**: May have bloody show, not typically heavy","ğŸ¦  **Membrane Status**: Ruptured membranes common","ğŸ’¥ **Cervical Motion**: Tenderness with movement","ğŸ”„ **Pelvic Adequacy**: Assessment for delivery planning","âš ï¸ **Gentle Examination**: Avoid unnecessary trauma"]},{title:"ğŸ‘¶ Fetal Assessment Findings",points:["ğŸ’“ **Fetal Heart Rate**: Persistent tachycardia >160 bpm","ğŸ“‰ **Variability**: May be reduced, concerning pattern","âš¡ **Decelerations**: Late decelerations if fetal compromise","ğŸ”„ **Movements**: Decreased fetal activity","ğŸ“Š **Biophysical Profile**: Reduced scores if severe","ğŸŒŠ **Amniotic Fluid**: Oligohydramnios, debris","ğŸ“ **Growth**: May show IUGR if chronic","âš ï¸ **Presentation**: Assess for delivery planning"]}]},{title:"ğŸ”¬ Comprehensive Diagnostic Workup",subsections:[{title:"ğŸ©¸ Laboratory Investigations",points:["ğŸ“Š **Complete Blood Count**:","  â€¢ Leukocytosis >15,000/Î¼L (85% cases)","  â€¢ Left shift >10% bands","  â€¢ May have leukopenia in severe sepsis","","ğŸ”¥ **Inflammatory Markers**:","  â€¢ C-reactive protein >100 mg/L","  â€¢ Procalcitonin >2.0 ng/mL","  â€¢ ESR elevated (non-specific)","","ğŸ§ª **Blood Chemistry**:","  â€¢ Glucose, electrolytes (sepsis monitoring)","  â€¢ Liver function tests (sepsis effects)","  â€¢ Renal function (creatinine, BUN)","  â€¢ Lactate level (sepsis marker)","","ğŸ©¸ **Blood Cultures**:","  â€¢ Two sets from different sites","  â€¢ Before antibiotic administration","  â€¢ Positive in 10-15% cases"]},{title:"ğŸŒŠ Amniotic Fluid Analysis",points:["ğŸ”¬ **Amniocentesis Indications**:","  â€¢ Unclear diagnosis, research settings","  â€¢ Generally not needed for clinical diagnosis","","ğŸ“Š **Amniotic Fluid Studies**:","  â€¢ White cell count >500/Î¼L","  â€¢ Glucose <15 mg/dL","  â€¢ Lactate dehydrogenase elevated","  â€¢ Protein >2.5 g/dL","","ğŸ¦  **Microbiological Studies**:","  â€¢ Gram stain - bacteria visible 50-60%","  â€¢ Culture - positive 70-80% clinical cases","  â€¢ Anaerobic culture essential","","ğŸ§¬ **Molecular Diagnostics**:","  â€¢ 16S rRNA PCR for bacteria","  â€¢ Broad-range bacterial PCR","  â€¢ Point-of-care tests under development"]},{title:"ğŸ”¬ Placental & Membrane Studies",points:["ğŸ§¬ **Histopathological Examination**:","  â€¢ Acute chorioamnionitis grading","  â€¢ Funisitis assessment","  â€¢ Villitis evaluation","","ğŸ¦  **Placental Cultures**:","  â€¢ Surface swab cultures","  â€¢ Deep tissue cultures","  â€¢ Anaerobic culture important","","ğŸ”¬ **Membrane Analysis**:","  â€¢ Histological examination","  â€¢ Bacterial invasion depth","  â€¢ Inflammatory cell infiltration patterns"]},{title:"ğŸ–¼ï¸ Imaging Studies",points:["ğŸ‘¶ **Obstetric Ultrasound**:","  â€¢ Amniotic fluid volume assessment","  â€¢ Fetal biophysical profile","  â€¢ Placental evaluation","  â€¢ Umbilical artery Doppler","","ğŸ“¸ **Maternal Imaging**:","  â€¢ Chest X-ray if respiratory symptoms","  â€¢ Abdominal CT if complications suspected","  â€¢ Pelvic ultrasound for collections","","ğŸ“± **Point-of-Care Ultrasound**:","  â€¢ Cardiac function assessment","  â€¢ Volume status evaluation","  â€¢ Lung ultrasound for complications"]}]},{title:"ğŸ’Š Comprehensive Treatment Protocols",subsections:[{title:"âš¡ Emergency Management (First Hour)",points:["ğŸš¨ **Immediate Assessment**:","  â€¢ ABC - Airway, Breathing, Circulation","  â€¢ Vital signs, mental status","  â€¢ IV access, blood cultures","","ğŸ’‰ **Empirical Antibiotics (Start Immediately)**:","  â€¢ **Standard**: Ampicillin 2g IV q6h + Gentamicin 5mg/kg IV q24h","  â€¢ **Alternative**: Ampicillin-sulbactam 3g IV q6h","  â€¢ **Penicillin Allergy**: Clindamycin 900mg IV q8h + Gentamicin","","âš¡ **Expedite Delivery**:","  â€¢ Regardless of gestational age","  â€¢ Vaginal delivery preferred if progressing","  â€¢ Cesarean section if obstetric indications","","ğŸ“Š **Monitoring Setup**:","  â€¢ Continuous fetal monitoring","  â€¢ Maternal vital signs q15 min","  â€¢ Urine output monitoring"]},{title:"ğŸ’Š Antibiotic Regimens",points:["ğŸ¥‡ **First-Line Regimen**:","  â€¢ Ampicillin 2g IV every 6 hours","  â€¢ Gentamicin 5mg/kg IV every 24 hours","  â€¢ Covers GBS, E.coli, Enterococcus","","ğŸ¥ˆ **Alternative Regimens**:","  â€¢ Ampicillin-sulbactam 3g IV q6h (monotherapy)","  â€¢ Piperacillin-tazobactam 4.5g IV q8h","  â€¢ Ertapenem 1g IV q24h (if ESBL risk)","","âš ï¸ **Penicillin Allergy**:","  â€¢ Clindamycin 900mg IV q8h + Gentamicin","  â€¢ Vancomycin 1g IV q12h + Gentamicin","","ğŸ“Š **Duration**:","  â€¢ Continue intrapartum","  â€¢ Postpartum until fever-free 48 hours","  â€¢ Usually 48-72 hours total"]},{title:"ğŸ¤° Delivery Management",points:["âš¡ **Timing**: Expedite delivery regardless of gestational age","","ğŸš¶ **Vaginal Delivery Preferred**:","  â€¢ If cervix favorable, progress adequate","  â€¢ Augment with oxytocin if needed","  â€¢ Continuous fetal monitoring","  â€¢ Episiotomy if needed for delivery","","ğŸ”ª **Cesarean Indications**:","  â€¢ Failed progress in labor","  â€¢ Fetal distress","  â€¢ Standard obstetric indications","  â€¢ Maternal deterioration","","ğŸ’Š **Perioperative Care**:","  â€¢ Continue antibiotics perioperatively","  â€¢ Standard surgical prophylaxis","  â€¢ Close monitoring for complications"]},{title:"ğŸ¥ Supportive Care",points:["ğŸ’§ **Fluid Management**:","  â€¢ Balanced crystalloids","  â€¢ Monitor input/output","  â€¢ Avoid fluid overload","","ğŸŒ¡ï¸ **Fever Control**:","  â€¢ Paracetamol 1g IV/PO q6h","  â€¢ Physical cooling measures","  â€¢ Target <38.5Â°C","","ğŸ’“ **Hemodynamic Support**:","  â€¢ Vasopressors if hypotensive","  â€¢ Central venous access if severe","  â€¢ Arterial line if ICU care","","ğŸ« **Respiratory Support**:","  â€¢ Oxygen therapy if needed","  â€¢ Monitor for ARDS","  â€¢ Mechanical ventilation if required"]}]},{title:"âš ï¸ Maternal Complications",subsections:[{title:"ğŸ”¥ Sepsis & Septic Shock",points:["ğŸ“Š **Incidence**: 10-15% of chorioamnionitis cases","âš¡ **Early Recognition**: qSOFA score â‰¥2 points","ğŸ’“ **Hemodynamic**: Hypotension, tachycardia, poor perfusion","ğŸ§  **Neurological**: Altered mental status, confusion","ğŸ« **Respiratory**: Tachypnea, hypoxemia, ARDS risk","ğŸ«˜ **Renal**: Oliguria, acute kidney injury","ğŸ’‰ **Management**: Early antibiotics, fluid resuscitation, vasopressors","ğŸ’€ **Mortality**: 15-25% if develops septic shock"]},{title:"ğŸ« Respiratory Complications",points:["ğŸ’§ **Pulmonary Edema**: Fluid overload, capillary leak","ğŸ« **ARDS**: 2-5% severe cases, high mortality","ğŸ¦  **Pneumonia**: Secondary bacterial, aspiration risk","âš¡ **Respiratory Failure**: Mechanical ventilation requirement","ğŸ’¨ **Pleural Effusion**: Inflammatory fluid accumulation","ğŸ”¥ **Pulmonary Embolism**: Hypercoagulable state","ğŸ’“ **Cor Pulmonale**: Right heart strain","ğŸ“Š **Management**: Lung-protective ventilation, PEEP optimization"]},{title:"ğŸ’“ Cardiovascular Complications",points:["ğŸ’€ **Septic Cardiomyopathy**: Reduced ejection fraction","âš¡ **Arrhythmias**: Atrial fibrillation, ventricular tachycardia","ğŸ©¸ **Hypotension**: Distributive shock pattern","ğŸ’§ **Fluid Overload**: Congestive heart failure","ğŸ”¥ **Pericarditis**: Inflammatory pericardial involvement","ğŸ’€ **Cardiac Arrest**: Terminal event in severe cases","ğŸ“Š **Monitoring**: Echocardiography, central venous pressure","ğŸ’Š **Treatment**: Inotropes, vasopressors, diuretics"]},{title:"ğŸ©¸ Hematological & Other Complications",points:["âš¡ **Disseminated Intravascular Coagulation**: 5-10% cases","ğŸ©¸ **Thrombocytopenia**: Platelet consumption, bleeding risk","ğŸ’€ **Acute Liver Failure**: Sepsis-induced hepatic dysfunction","ğŸ«˜ **Acute Kidney Injury**: Prerenal, septic nephropathy","ğŸ§  **Encephalopathy**: Septic, hepatic, uremic causes","ğŸ¦´ **Adrenal Insufficiency**: Relative adrenal insufficiency","ğŸ’§ **Electrolyte Imbalance**: Hyponatremia, hyperkalemia","ğŸ”¥ **Multi-organ Dysfunction**: Sequential organ failure"]}]},{title:"ğŸ‘¶ Fetal, Neonatal & Long-term Effects",subsections:[{title:"ğŸ¤° Immediate Fetal Effects",points:["ğŸ’“ **Fetal Inflammatory Response Syndrome (FIRS)**:","  â€¢ Fetal IL-6 >17.5 pg/mL","  â€¢ Associated with cerebral palsy risk","  â€¢ Multi-organ fetal involvement","","âš¡ **Fetal Distress**:","  â€¢ Persistent tachycardia >160 bpm","  â€¢ Reduced heart rate variability","  â€¢ Late decelerations with contractions","","ğŸ’€ **Fetal Demise**:","  â€¢ 5-10% risk if untreated","  â€¢ Higher risk in preterm gestations","  â€¢ Associated with severe maternal sepsis","","ğŸ§  **Neurological Effects**:","  â€¢ Periventricular leukomalacia","  â€¢ Intraventricular hemorrhage","  â€¢ Cerebral palsy risk increased 3-4x"]},{title:"ğŸ‘¶ Neonatal Complications",points:["ğŸ¦  **Early-Onset Sepsis**:","  â€¢ 15-25% of exposed infants","  â€¢ Symptoms within 72 hours","  â€¢ High mortality if untreated","","ğŸ« **Respiratory Complications**:","  â€¢ Respiratory distress syndrome","  â€¢ Persistent pulmonary hypertension","  â€¢ Mechanical ventilation requirement","","ğŸ§  **Neurological Sequelae**:","  â€¢ Seizures, encephalopathy","  â€¢ Cerebral palsy (3-4x increased risk)","  â€¢ Developmental delays","","ğŸ”¥ **Systemic Effects**:","  â€¢ Necrotizing enterocolitis","  â€¢ Retinopathy of prematurity","  â€¢ Bronchopulmonary dysplasia","  â€¢ Failure to thrive"]},{title:"ğŸ“ˆ Long-term Developmental Effects",points:["ğŸ§  **Neurodevelopmental Outcomes**:","  â€¢ Cerebral palsy: 3-4 fold increased risk","  â€¢ Cognitive delays: 15-25% of survivors","  â€¢ Learning disabilities: Higher prevalence","  â€¢ Autism spectrum disorders: Possible association","","ğŸ“š **Educational Impact**:","  â€¢ Special education needs increased","  â€¢ Lower IQ scores on average","  â€¢ Language development delays","  â€¢ Behavioral problems in school","","ğŸ‘‚ **Sensory Impairments**:","  â€¢ Hearing loss: 2-3% of survivors","  â€¢ Visual impairment: Retinal damage","  â€¢ Sensory processing disorders","","ğŸ’ª **Physical Development**:","  â€¢ Growth restriction patterns","  â€¢ Motor development delays","  â€¢ Chronic health conditions","  â€¢ Reduced physical fitness"]},{title:"ğŸ¥ Neonatal Management Protocols",points:["ğŸš¨ **Immediate Assessment**:","  â€¢ Resuscitation team present","  â€¢ Blood cultures before antibiotics","  â€¢ Complete blood count, blood gas","","ğŸ’Š **Empirical Antibiotics**:","  â€¢ Ampicillin + gentamicin","  â€¢ Start within 1 hour if symptomatic","  â€¢ Continue based on culture results","","ğŸ“Š **Monitoring**:","  â€¢ Continuous cardiorespiratory monitoring","  â€¢ Blood glucose, electrolytes","  â€¢ Neurological assessment","","ğŸ‘ï¸ **Follow-up**:","  â€¢ Early intervention programs","  â€¢ Neurodevelopmental assessment","  â€¢ Hearing and vision screening","  â€¢ Long-term pediatric care"]}]},{title:"ğŸ›¡ï¸ Prevention Strategies",subsections:[{title:"ğŸ¥ Intrapartum Prevention",points:["ğŸ¤² **Sterile Technique**: Minimize vaginal examinations","ğŸ§¤ **Hand Hygiene**: Strict handwashing protocols","â° **Limit Examinations**: <5 vaginal exams recommended","ğŸ’§ **Membrane Management**: Avoid artificial rupture unless indicated","ğŸš¿ **Antiseptic Preparation**: Chlorhexidine vaginal preparation","ğŸ’Š **GBS Prophylaxis**: Appropriate antibiotic prophylaxis","âš¡ **Labor Duration**: Avoid prolonged labor >18 hours","ğŸ“Š **Monitoring**: Early recognition of signs"]},{title:"ğŸ¤° Antepartum Prevention",points:["ğŸ” **Risk Assessment**: Identify high-risk pregnancies","ğŸ¦  **Infection Screening**: GBS, UTI, BV screening","ğŸ’Š **Antibiotic Treatment**: Treat active infections","ğŸ¥ **Antenatal Care**: Regular prenatal visits","ğŸ“š **Patient Education**: Warning signs, when to seek care","ğŸš¿ **Hygiene Education**: Proper perineal hygiene","ğŸ½ï¸ **Nutrition**: Adequate protein, immune support","ğŸ’‰ **Vaccination**: Influenza, Tdap as indicated"]},{title:"ğŸ¥ Healthcare System Prevention",points:["ğŸ“‹ **Clinical Guidelines**: Evidence-based protocols","ğŸ‘¨â€âš•ï¸ **Staff Training**: Recognition and management","ğŸ”¬ **Laboratory Support**: Rapid diagnostic testing","ğŸ’Š **Antibiotic Availability**: Appropriate antimicrobials","ğŸ“Š **Quality Metrics**: Infection rate monitoring","ğŸ¤ **Multidisciplinary**: Obstetric-pediatric coordination","ğŸ“± **Communication**: Early warning systems","ğŸ’° **Resource Allocation**: Adequate staffing, equipment"]}]},{title:"ğŸ‡°ğŸ‡ª Kenya-Specific Considerations",points:["ğŸ¥ **Healthcare Access**: Limited ICU facilities, delayed referrals","ğŸ’Š **Antibiotic Resistance**: Increasing ESBL-producing organisms","ğŸ¦  **HIV Co-infection**: 15-20% prevalence, affects immune response","ğŸ  **Home Births**: Traditional birth attendants, delayed recognition","ğŸ’° **Socioeconomic**: Poverty affects healthcare seeking behavior","ğŸ˜ï¸ **Urban Slums**: Overcrowding, poor hygiene conditions","ğŸ“± **mHealth**: Mobile platforms for education, early warning","ğŸ¤ **Community**: Traditional practices, cultural beliefs","ğŸŒ§ï¸ **Seasonal**: Rainy season increases infection risk","ğŸ“Š **Surveillance**: Improving reporting, outcome tracking"]},{title:"Chorioamnionitis â€“ Visual Algorithm (Tabbed)",points:["**TAB_START: Flowchart**","```mermaid","flowchart TD","  A[Diagnose (fever + criteria)] --> B[Blood cultures if â‰¤45 min delay]","  B --> C[Start broad-spectrum antibiotics]","  C --> D[Expedite delivery]","  D --> E[Postpartum antibiotics until afebrile 24â€“48h]","  E --> F[Neonatal sepsis pathway and cultures]","```","**TAB_END**","**TAB_START: Checklist**","1-hour bundle; maternal/fetal monitoring; delivery planning; neonatal team activation; documentation and debrief","**TAB_END**"]},{title:"Postpartum Antibiotics and Discharge Criteria",points:["â€¢ Continue antibiotics until afebrile 24â€“48 h","â€¢ Regimens per local protocol; ensure culture follow-up","â€¢ Discharge when clinically improved with clear neonatal plan"]}];export{e as getChorioamnionitisContent};
